IDH2 and acute myeloid leukemia: The NCT02677922 trial is a phase Ib/II study investigating the efficacy and safety of ivosidenib or enasidenib combined with azacytidine in untreated, IDH-mutated AML considered ineligible for intensive chemotherapy.